BioStock: Fluicell at the forefront of 3D bioprinting

Drug discovery and development is extremely time-consuming. To facilitate the drug discovery process, biotech companies have set out to develop new tools aimed at helping researchers get better results at lower costs. One example is Fluicell, a Swedish company with a strong product portfolio with the promise of answering that call. We caught up with the company’s CEO, Dr Victoire Viannay, to learn more about their technology.

Read the full interview with Fluicell's CEO Victoire Viannay at biostock.se:

https://www.biostock.se/en/fluicell-at-the-forefront-of-3d-bioprinting/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Quick facts

BioStock: Fluicell at the forefront of 3D bioprinting
Tweet this